Loading...
Header Logo
Keywords
Last Name
Institution

JAMES N YANG

TitleAssociate Professor
InstitutionMD Anderson
DepartmentRadiation Physics
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lee KWC, Lord SJ, Kasherman L, Marschner I, Stockler M, Gralla R, Yang JC, Mok T, Lee CK. The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. Acta Oncol. 2019 Sep 25; 1-5. PMID: 31552770.
      View in: PubMed
    2. Chatani PD, Yang JC. Mutated RAS: Targeting the "Untargetable" with T-cells. Clin Cancer Res. 2019 Sep 11. PMID: 31511296.
      View in: PubMed
    3. Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, Dyson KA, Grippin AJ, Deleyrolle LP, Zhang W, Rajon DA, Wang QJ, Yang JC, Kresak JL, Sayour EJ, Rahman M, Bova FJ, Lin Z, Mitchell DA, Huang J. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019 Sep 05; 10(1):4016. PMID: 31488817.
      View in: PubMed
    4. Hong ST, Lin H, Wang CS, Chang CH, Lin AM, Yang JC, Lo YL. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. J Nanobiotechnology. 2019 Aug 19; 17(1):89. PMID: 31426807.
      View in: PubMed
    5. Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. J Clin Oncol. 2019 Oct 20; 37(30):2759-2768. PMID: 31408414.
      View in: PubMed
    6. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019 Sep; 15(25):2905-2914. PMID: 31370698.
      View in: PubMed
    7. Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS. Osimertinib in Patients with T790M Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Res Treat. 2019 Jul 23. PMID: 31345012.
      View in: PubMed
    8. Wu TH, Hsiue EH, Yang JC. Opportunities of circulating tumor DNA in lung cancer. Cancer Treat Rev. 2019 Aug; 78:31-41. PMID: 31326635.
      View in: PubMed
    9. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang JC, Yu CJ. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019 Aug; 117:107-115. PMID: 31279301.
      View in: PubMed
    10. Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis CR, Millward M, Lord S, Gralla RJ, Yang JC, Mok T, Lee CK. Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncol. 2019 Jul; 15(20):2371-2383. PMID: 31354046.
      View in: PubMed
    11. Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist. 2019 May 24. PMID: 31127020.
      View in: PubMed
    12. Liang SK, Ko JC, Yang JC, Shih JY. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019 Jul; 133:103-109. PMID: 31200815.
      View in: PubMed
    13. Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother. 2019 May; 42(4):126-135. PMID: 30882547.
      View in: PubMed
    14. Chumacero EA, Yang J. Basin of Attraction and Limit Cycle Amplitude of an Ankle-Hip Model of Balance on a Balance Board. J Biomech Eng. 2019 Apr 24. PMID: 31017633.
      View in: PubMed
    15. Park K, Wan-Teck Lim D, Okamoto I, Yang JC. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med Oncol. 2019; 11:1758835919836374. PMID: 31019567.
      View in: PubMed
    16. Jafferji MS, Yang JC. Adoptive T-Cell Therapy for Solid Malignancies. Surg Oncol Clin N Am. 2019 Jul; 28(3):465-479. PMID: 31079800.
      View in: PubMed
    17. Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2019 Jun; 132:126-131. PMID: 31097085.
      View in: PubMed
    18. Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 2019 Jul; 133:10-19. PMID: 31200814.
      View in: PubMed
    19. Yang JC. Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? Lancet Oncol. 2019 May; 20(5):602-603. PMID: 30975629.
      View in: PubMed
    20. Xu M, Yang J, Lieberman IH, Haddas R. Finite element method-based study of pedicle screw-bone connection in pullout test and physiological spinal loads. Med Eng Phys. 2019 05; 67:11-21. PMID: 30879945.
      View in: PubMed
    21. Hsiue EH, Lee PL, Chen YH, Wu TH, Cheng CF, Cheng KM, Yang PC, Chen HW, Lin PY, Chiang DL, Wu HD, Yang JC, Yu CJ. Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. J Formos Med Assoc. 2019 Jun; 118(6):995-1004. PMID: 30857753.
      View in: PubMed
    22. Lee JH, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2019 Mar 02. PMID: 30825104.
      View in: PubMed
    23. Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol. 2019 Jun; 145(6):1569-1579. PMID: 30783814.
      View in: PubMed
    24. Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC. Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. Target Oncol. 2019 02; 14(1):57-65. PMID: 30725402.
      View in: PubMed
    25. Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896. PMID: 30485437.
      View in: PubMed
    26. Stevanovic S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. Clin Cancer Res. 2019 Mar 01; 25(5):1486-1493. PMID: 30518633.
      View in: PubMed
    27. Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2019 Mar; 14(3):553-559. PMID: 30529597.
      View in: PubMed
    28. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 Mar 15; 125(6):892-901. PMID: 30512189.
      View in: PubMed
    29. Yang Q, Li H, Shen S, Zhang G, Huang R, Feng Y, Yang J, Ma S. Study of the micro-climate and bacterial distribution in the deadspace of N95 filtering face respirators. Sci Rep. 2018 11 26; 8(1):17382. PMID: 30478258.
      View in: PubMed
    30. Xu M, Yang J, Lieberman I, Haddas R. Stress distribution in vertebral bone and pedicle screw and screw-bone load transfers among various fixation methods for lumbar spine surgical alignment: A finite element study. Med Eng Phys. 2019 01; 63:26-32. PMID: 30344069.
      View in: PubMed
    31. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018 Nov; 14(27):2861-2874. PMID: 30336693.
      View in: PubMed
    32. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 11 22; 379(21):2027-2039. PMID: 30280657.
      View in: PubMed
    33. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 11 01; 36(31):3101-3109. PMID: 30156984.
      View in: PubMed
    34. Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018 11; 125:273-281. PMID: 30429032.
      View in: PubMed
    35. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 Jan; 14(1):124-129. PMID: 30138764.
      View in: PubMed
    36. Wu SG, Liu YN, Yu CJ, Yang JC, Shih JY. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosomes Cancer. 2018 10; 57(10):513-521. PMID: 30107055.
      View in: PubMed
    37. Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer Sci. 2018 Sep; 109(9):2852-2862. PMID: 29972716.
      View in: PubMed
    38. Gebski V, Yang JC, Lee CK. Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. JAMA Oncol. 2018 08 01; 4(8):1138-1139. PMID: 29931217.
      View in: PubMed
    39. Mehta GU, Malekzadeh P, Shelton T, White DE, Butman JA, Yang JC, Kammula US, Goff SL, Rosenberg SA, Sherry RM. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. J Immunother. 2018 Jun; 41(5):241-247. PMID: 29672342.
      View in: PubMed
    40. Chumacero E, Yang J, Chagdes JR. Effect of sensory-motor latencies and active muscular stiffness on stability for an ankle-hip model of balance on a balance board. J Biomech. 2018 06 25; 75:77-88. PMID: 29861093.
      View in: PubMed
    41. Liao BC, Lin CC, Yang JC. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother. 2018 06; 19(8):851-864. PMID: 29726292.
      View in: PubMed
    42. Wu TH, Lee LJ, Yuan CT, Chen TW, Yang JC. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study. J Formos Med Assoc. 2019 Jan; 118(1 Pt 2):230-236. PMID: 29709339.
      View in: PubMed
    43. Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. J Cancer. 2018; 9(10):1813-1820. PMID: 29805708.
      View in: PubMed
    44. Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, Lee JM, Lee YW, Choi JW, Kim HR, Hong MH, Haam K, Huh N, Kim JH, Kim YS, Shim HS, Soo RA, Shih JY, Yang JC, Kim M, Cho BC. Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. Cancer Res. 2018 06 15; 78(12):3350-3362. PMID: 29669761.
      View in: PubMed
    45. Yan Y, Yang J, Beddar S, Ibbott G, Wen Z, Court LE, Hwang KP, Kadbi M, Krishnan S, Fuller CD, Frank SJ, Yang J, Balter P, Kudchadker RJ, Wang J. A methodology to investigate the impact of image distortions on the radiation dose when using magnetic resonance images for planning. Phys Med Biol. 2018 04 05; 63(8):085005. PMID: 29528037.
      View in: PubMed
    46. Wu TH, Yang JC. Real-World or Controlled Clinical Trial Data in Real-World Practice. J Thorac Oncol. 2018 04; 13(4):470-472. PMID: 29576285.
      View in: PubMed
    47. Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clin Drug Investig. 2018 Apr; 38(4):319-331. PMID: 29247383.
      View in: PubMed
    48. Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 05 10; 36(14):1405-1411. PMID: 29596029.
      View in: PubMed
    49. Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 01; 4(2):210-216. PMID: 29270615.
      View in: PubMed
    50. Wu TH, Hsiue EH, Lee JH, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. Clin Lung Cancer. 2018 05; 19(3):e361-e372. PMID: 29477365.
      View in: PubMed
    51. Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient. 2018 02; 11(1):131-141. PMID: 29178024.
      View in: PubMed
    52. Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, Sayour EJ, De Leon G, Wang QJ, Yang JC, Kubilis PS, Bao H, Xia S, Lu D, Kong Y, Hu L, Shang Y, Jiang C, Nie J, Li S, Gu Y, Sun J, Mitchell DA, Lin Z, Huang J. CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol. 2018 01 10; 20(1):55-65. PMID: 28651374.
      View in: PubMed
    53. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018 02; 6(2):107-116. PMID: 29249325.
      View in: PubMed
    54. Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018 01; 118(1):38-42. PMID: 29149104.
      View in: PubMed
    55. Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers. Sci Transl Med. 2017 Nov 08; 9(415). PMID: 29118262.
      View in: PubMed
    56. Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang JC, Kuo SH, Cheng JC, Yang PC, Hsu FM. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol. 2018 Feb; 126(2):368-374. PMID: 29111173.
      View in: PubMed
    57. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017 11; 5(11):891-902. PMID: 29056570.
      View in: PubMed
    58. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034. PMID: 28968167.
      View in: PubMed
    59. Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017 Nov 10; 35(32):3662-3670. PMID: 28902534.
      View in: PubMed
    60. Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 03 20; 36(9):841-849. PMID: 28841389.
      View in: PubMed
    61. Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329. PMID: 28809608.
      View in: PubMed
    62. Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J, Gold KA, Cantarini M, Barrett JC, Jänne PA. Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. J Thorac Oncol. 2017 10; 12(10):1588-1594. PMID: 28751247.
      View in: PubMed
    63. Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, McIntyre L, Bot A, Rossi J, Lam N, Rosenberg SA. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017 10 04; 25(10):2245-2253. PMID: 28803861.
      View in: PubMed
    64. Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017 09; 82:27-33. PMID: 28646771.
      View in: PubMed
    65. Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 10; 12(10):1552-1560. PMID: 28689043.
      View in: PubMed
    66. Yang JC, Mok T, Han B, Orlando M, Puri T, Park K. A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 01; 19(1):27-34. PMID: 28743421.
      View in: PubMed
    67. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048. PMID: 28687375.
      View in: PubMed
    68. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017 Jun 20; 8(25):41474-41486. PMID: 28467813.
      View in: PubMed
    69. Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst. 2017 06 01; 109(6). PMID: 28376144.
      View in: PubMed
    70. Chen D, Yang J. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. Transl Res. 2017 09; 187:11-21. PMID: 28641074.
      View in: PubMed
    71. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
      View in: PubMed
    72. Liao BC, Lin CC, Lee JH, Yang JC. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer. 2017 08; 110:7-13. PMID: 28676222.
      View in: PubMed
    73. Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, Hodge R, Cantarini M, Jänne PA, Mitsudomi T, Goss GD. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 07; 12(7):1061-1070. PMID: 28428148.
      View in: PubMed
    74. Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017 06; 18(6):792-802. PMID: 28395880.
      View in: PubMed
    75. Xu M, Yang J, Lieberman I, Haddas R. Finite element method-based study for effect of adult degenerative scoliosis on the spinal vibration characteristics. Comput Biol Med. 2017 05 01; 84:53-58. PMID: 28342408.
      View in: PubMed
    76. Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 2017 Jun 01; 35(16):1803-1813. PMID: 28291388.
      View in: PubMed
    77. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. PMID: 28447912.
      View in: PubMed
    78. Yang JC. Debugging the Black Box. Cancer Discov. 2017 03; 7(3):250-251. PMID: 28264866.
      View in: PubMed
    79. Chang IS, Jiang SS, Yang JC, Su WC, Chien LH, Hsiao CF, Lee JH, Chen CY, Chen CH, Chang GC, Wang Z, Lo FY, Chen KY, Wang WC, Chen YM, Huang MS, Tsai YH, Su YC, Hsieh WS, Shih WC, Shieh SH, Yang TY, Lan Q, Rothman N, Chen CJ, Chanock SJ, Yang PC, Hsiung CA. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. Am J Respir Crit Care Med. 2017 03 01; 195(5):663-673. PMID: 27669169.
      View in: PubMed
    80. Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20; 35(12):1288-1296. PMID: 28221867.
      View in: PubMed
    81. Pati D, Valipoor S, Cloutier A, Yang J, Freier P, Harvey TE, Lee J. Physical Design Factors Contributing to Patient Falls. J Patient Saf. 2017 Feb 03. PMID: 28157790.
      View in: PubMed
    82. Park TS, Phan GQ, Yang JC, Kammula U, Hughes MS, Trebska-McGowan K, Morton KE, White DE, Rosenberg SA, Sherry RM. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Ann Surg Oncol. 2017 Apr; 24(4):947-951. PMID: 28144760.
      View in: PubMed
    83. Liao BC, Lin CC, Yang JC. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep. 2017 Jan; 19(1):4. PMID: 28138934.
      View in: PubMed
    84. Lin YT, Liu YN, Wu SG, Yang JC, Shih JY. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 05; 18(3):324-332.e1. PMID: 28089594.
      View in: PubMed
    85. Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, Kim M, Yang JC. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017 Jan 17; 116(2):175-185. PMID: 28006816.
      View in: PubMed
    86. Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 04; 12(4):633-643. PMID: 28007626.
      View in: PubMed
    87. Wu TH, Hsiue EH, Lee JH, Lin CC, Yang JC. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Expert Rev Respir Med. 2017 01; 11(1):51-55. PMID: 27927060.
      View in: PubMed
    88. Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, Xu Y, Yin X, Bai Y, Rabbie S, Kim DW, Ahn MJ, Yang JC, Zhang X. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016 12 07; 8(368):368ra172. PMID: 27928026.
      View in: PubMed
    89. Yang JC, Puri T, Orlando M, Cheng Y. Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. J Clin Oncol. 2017 02 20; 35(6):694-695. PMID: 27918723.
      View in: PubMed
    90. Liao BC, Lin CC, Lee JH, Yang JC. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. J Biomed Sci. 2016 Dec 03; 23(1):86. PMID: 27912760.
      View in: PubMed
    91. Lin KH, Hong ST, Wang HT, Lo YL, Lin AM, Yang JC. Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One a-Helical Cell-Penetrating Peptide or Glutathione and Tween 80. Int J Mol Sci. 2016 Nov 29; 17(12). PMID: 27916828.
      View in: PubMed
    92. Biswas R, Gao S, Cultraro CM, Maity TK, Venugopalan A, Abdullaev Z, Shaytan AK, Carter CA, Thomas A, Rajan A, Song Y, Pitts S, Chen K, Bass S, Boland J, Hanada KI, Chen J, Meltzer PS, Panchenko AR, Yang JC, Pack S, Giaccone G, Schrump DS, Khan J, Guha U. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Cold Spring Harb Mol Case Stud. 2016 11; 2(6):a001263. PMID: 27900369.
      View in: PubMed
    93. Wang QJ, Yu Z, Hanada KI, Patel K, Kleiner D, Restifo NP, Yang JC. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clin Cancer Res. 2017 May 01; 23(9):2267-2276. PMID: 27803044.
      View in: PubMed
    94. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 12; 34(34):4079-4085. PMID: 27863201.
      View in: PubMed
    95. Hsiue EH, Lee JH, Lin CC, Yang JC. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagn. 2016 12; 16(12):1251-1257. PMID: 27737606.
      View in: PubMed
    96. Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. J Thorac Oncol. 2017 02; 12(2):403-407. PMID: 27765535.
      View in: PubMed
    97. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov; 17(11):1497-1508. PMID: 27745820.
      View in: PubMed
    98. Gragg J, Klose E, Yang J. Modelling the stochastic nature of the available coefficient of friction at footwear-floor interfaces. Ergonomics. 2017 Jul; 60(7):977-984. PMID: 27592564.
      View in: PubMed
    99. Klemen ND, Feingold PL, Goff SL, Hughes MS, Kammula US, Yang JC, Schrump DS, Rosenberg SA, Sherry RM. Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Ann Surg Oncol. 2017 Jan; 24(1):135-141. PMID: 27638681.
      View in: PubMed
    100. Lu SL, Hsu FM, Chen KY, Ho CC, Yang JC, Cheng JC. Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. Case Rep Oncol. 2016 May-Aug; 9(2):474-480. PMID: 27721771.
      View in: PubMed
    101. Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. J Clin Oncol. 2016 09 20; 34(27):3258-66. PMID: 27507876.
      View in: PubMed
    102. Mok TS, Geater SL, Su WC, Tan EH, Yang JC, Chang GC, Han M, Komarnitsky P, Payumo F, Garrus JE, Close S, Park K. A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. J Thorac Oncol. 2016 10; 11(10):1736-44. PMID: 27448761.
      View in: PubMed
    103. Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016 Oct 15; 22(20):5130-5140. PMID: 27435396.
      View in: PubMed
    104. Liang YH, Shao YY, Liao BC, Lee HS, Yang JC, Chen HM, Chiang CJ, Cheng AL, Lai MS. Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. J Cancer. 2016; 7(11):1515-23. PMID: 27471567.
      View in: PubMed
    105. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 10 01; 34(28):3375-82. PMID: 27354477.
      View in: PubMed
    106. Xu M, Yang J, Lieberman IH, Haddas R. Lumbar spine finite element model for healthy subjects: development and validation. Comput Methods Biomech Biomed Engin. 2017 Jan; 20(1):1-15. PMID: 27315668.
      View in: PubMed
    107. Hsiue EH, Lee JH, Lin CC, Yang JC. Safety of gefitinib in non-small cell lung cancer treatment. Expert Opin Drug Saf. 2016 Jul; 15(7):993-1000. PMID: 27212579.
      View in: PubMed
    108. Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol. 2016 07 10; 34(20):2389-97. PMID: 27217459.
      View in: PubMed
    109. Chen YF, Hsieh MS, Wu SG, Chang YL, Yu CJ, Yang JC, Yang PC, Shih JY. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. J Thorac Oncol. 2016 07; 11(7):1140-52. PMID: 27094798.
      View in: PubMed
    110. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 05; 17(5):577-89. PMID: 27083334.
      View in: PubMed
    111. Lin YT, Yu CJ, Yang JC, Shih JY. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 09; 17(5):e77-e94. PMID: 27130468.
      View in: PubMed
    112. Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016 Mar 15; 7(11):12404-13. PMID: 26862733.
      View in: PubMed
    113. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016 Apr; 22(4):433-8. PMID: 26901407.
      View in: PubMed
    114. Yang JC, Rosenberg SA. Adoptive T-Cell Therapy for Cancer. Adv Immunol. 2016; 130:279-94. PMID: 26923004.
      View in: PubMed
    115. Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang JC, Rosell R, Yang PC. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016 Apr; 94:46-53. PMID: 26973206.
      View in: PubMed
    116. Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016 Mar; 11(3):380-90. PMID: 26823294.
      View in: PubMed
    117. Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, Lan KH, Cheng AL, Kuo SH. The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS One. 2015; 10(12):e0145936. PMID: 26720170.
      View in: PubMed
    118. Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. J Thorac Oncol. 2016 Mar; 11(3):370-9. PMID: 26725183.
      View in: PubMed
    119. Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol Res. 2016 Mar; 4(3):204-14. PMID: 26701267.
      View in: PubMed
    120. Boye M, Wang X, Srimuninnimit V, Kang JH, Tsai CM, Orlando M, Puri T, Kim JS, Rajan N, Yang JC. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clin Lung Cancer. 2016 Mar; 17(2):150-60. PMID: 26809984.
      View in: PubMed
    121. Ilyas S, Yang JC. Landscape of Tumor Antigens in T Cell Immunotherapy. J Immunol. 2015 Dec 01; 195(11):5117-22. PMID: 26589749.
      View in: PubMed
    122. Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. J Thorac Oncol. 2015 Dec; 10(12):1745-53. PMID: 26743856.
      View in: PubMed
    123. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. J Thorac Oncol. 2015 Dec; 10(12):1754-61. PMID: 26334749.
      View in: PubMed
    124. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2016 Mar 01; 34(7):661-8. PMID: 26598747.
      View in: PubMed
    125. Yang JC. Toxicities Associated With Adoptive T-Cell Transfer for Cancer. Cancer J. 2015 Nov-Dec; 21(6):506-9. PMID: 26588684.
      View in: PubMed
    126. Yang JC. The Immunotherapy Roadmap. Clin Cancer Res. 2016 Jan 15; 22(2):275-6. PMID: 26459176.
      View in: PubMed
    127. Wu H, Shih JY, Yang JC. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. J Thorac Oncol. 2015 Sep; 10(9):e95-e96. PMID: 26291023.
      View in: PubMed
    128. Liao BC, Lin CC, Shih JY, Yang JC. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol. 2015 Sep; 7(5):274-90. PMID: 26327925.
      View in: PubMed
    129. Kuo HY, Lin ZZ, Kuo R, Shau WY, Lai CL, Yang YY, Shao YY, Hsu C, Cheng WF, Cheng AL, Yang JC, Lai MS. The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. Oncologist. 2015 Sep; 20(9):1051-7. PMID: 26240133.
      View in: PubMed
    130. Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug; 16(8):990-8. PMID: 26159065.
      View in: PubMed
    131. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul; 16(7):830-8. PMID: 26051236.
      View in: PubMed
    132. Tang C, Hess K, Bishop AJ, Pan HY, Christensen EN, Yang JN, Tannir N, Amini B, Tatsui C, Rhines L, Brown P, Ghia A. Creation of a Prognostic Index for Spine Metastasis to Stratify Survival in Patients Treated With Spinal Stereotactic Radiosurgery: Secondary Analysis of Mature Prospective Trials. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):118-25. PMID: 26130231.
      View in: PubMed
    133. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1689-99. PMID: 25923549.
      View in: PubMed
    134. Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH, Chen HY, Yu SL, Yang JC, Shih JY. IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget. 2015 Apr 30; 6(12):10415-31. PMID: 25871388.
      View in: PubMed
    135. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015 Jun 20; 33(18):2092-9. PMID: 25918278.
      View in: PubMed
    136. Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol. 2015 Jun 10; 33(17):1958-65. PMID: 25897154.
      View in: PubMed
    137. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10; 33(14):1543-50. PMID: 25823737.
      View in: PubMed
    138. Tang MC, Wu MY, Hwang MH, Chang YT, Huang HJ, Lin AM, Yang JC. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. PLoS One. 2015; 10(3):e0119135. PMID: 25807554.
      View in: PubMed
    139. Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer. 2015 May; 88(2):208-14. PMID: 25773866.
      View in: PubMed
    140. Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Mar; 27(2):94-101. PMID: 25611025.
      View in: PubMed
    141. Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC, Rosenberg SA. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015 May 15; 21(10):2278-88. PMID: 25695689.
      View in: PubMed
    142. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb; 16(2):141-51. PMID: 25589191.
      View in: PubMed
    143. Gragg J, Yang J. Predicting the probability of slip in gait: methodology and distribution study. Comput Methods Biomech Biomed Engin. 2016; 19(1):93-100. PMID: 25563532.
      View in: PubMed
    144. Xu M, Lei Z, Yang J. Estimating the Dead Space Volume Between a Headform and N95 Filtering Facepiece Respirator Using Microsoft Kinect. J Occup Environ Hyg. 2015; 12(8):538-46. PMID: 25800663.
      View in: PubMed
    145. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015 Mar 01; 21(5):1019-27. PMID: 25538264.
      View in: PubMed
    146. Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res. 2015 Feb 01; 21(3):534-43. PMID: 25424856.
      View in: PubMed
    147. Klawikowski SJ, Yang JN, Adamovics J, Ibbott GS. PRESAGE 3D dosimetry accurately measures Gamma Knife output factors. Phys Med Biol. 2014 Dec 07; 59(23):N211-20. PMID: 25368961.
      View in: PubMed
    148. Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, Yang PC. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2014 Nov; 9(11):1720-5. PMID: 25436806.
      View in: PubMed
    149. Yang JC, Sherry RM. MSLT-I-response of clinical trial investigators. Nat Rev Clin Oncol. 2014 Nov; 11(11). PMID: 25311346.
      View in: PubMed
    150. Liao BC, Shao YY, Chen HM, Shau WY, Lin ZZ, Kuo RN, Lai CL, Chen KH, Cheng AL, Yang JC, Lai MS. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Clin Lung Cancer. 2015 Mar; 16(2):137-43. PMID: 25450871.
      View in: PubMed
    151. Hsu CL, Chen JH, Chen KY, Shih JY, Yang JC, Yu CJ, Yang PC. Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. J Geriatr Oncol. 2015 Jan; 6(1):38-45. PMID: 25245172.
      View in: PubMed
    152. Lei Z, Ji X, Li N, Yang J, Zhuang Z, Rottach D. Simulated effects of head movement on contact pressures between headforms and N95 filtering facepiece respirators-part 1: headform model and validation. Ann Occup Hyg. 2014 Nov; 58(9):1175-85. PMID: 25187034.
      View in: PubMed
    153. Lei Z, Ji X, Li N, Yang J, Zhuang Z, Rottach D. Simulated effects of head movement on contact pressures between headforms and N95 filtering facepiece respirators part 2: simulation. Ann Occup Hyg. 2014 Nov; 58(9):1186-99. PMID: 25187035.
      View in: PubMed
    154. Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). J Thorac Oncol. 2014 Sep; 9(9):1411-7. PMID: 25122437.
      View in: PubMed
    155. Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T. Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers. Cancer Res. 2014 Sep 01; 74(17):4653-62. PMID: 25183789.
      View in: PubMed
    156. Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC, Laio WY, Yang PC, Yang JC. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Sep; 9(9):1385-92. PMID: 25057939.
      View in: PubMed
    157. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20; 33(6):540-9. PMID: 25154820.
      View in: PubMed
    158. Chen YF, Hsieh MS, Wu SG, Chang YL, Shih JY, Liu YN, Tsai MF, Tsai TH, Yu CJ, Yang JC, Yang PC. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014 Aug; 9(8):1171-9. PMID: 25157770.
      View in: PubMed
    159. Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014 Jul 01; 20(13):3401-10. PMID: 24987109.
      View in: PubMed
    160. Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep; 50(13):2219-30. PMID: 24953333.
      View in: PubMed
    161. Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. Lung Cancer. 2014 Aug; 85(2):230-8. PMID: 24929780.
      View in: PubMed
    162. Li J, Yang J, Levin AM, Montgomery CG, Datta I, Trudeau S, Adrianto I, McKeigue P, Iannuzzi MC, Rybicki BA. Efficient generalized least squares method for mixed population and family-based samples in genome-wide association studies. Genet Epidemiol. 2014 Jul; 38(5):430-8. PMID: 24845555.
      View in: PubMed
    163. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 09; 344(6184):641-5. PMID: 24812403.
      View in: PubMed
    164. Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol. 2014 Aug; 21(8):2484-9. PMID: 24756814.
      View in: PubMed
    165. Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget. 2014 Apr 15; 5(7):1701-52. PMID: 24743024.
      View in: PubMed
    166. Yang JC, Sherry RM, Rosenberg SA. Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma? Nat Rev Clin Oncol. 2014 May; 11(5):245-6. PMID: 24732941.
      View in: PubMed
    167. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA. PD-1 identifies the patient-specific CD8? tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014 May; 124(5):2246-59. PMID: 24667641.
      View in: PubMed
    168. Yang JC, Sequist LV. Reply to F. De Marinis et al. J Clin Oncol. 2014 Mar 10; 32(8):865. PMID: 24493733.
      View in: PubMed
    169. Yang JC, Sequist LV. Reply to E.R. Haspinger et al. J Clin Oncol. 2014 Mar 10; 32(8):863-4. PMID: 24493734.
      View in: PubMed
    170. Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014 May 01; 120(9):1426-32. PMID: 24474396.
      View in: PubMed
    171. Kao HF, Chen IC, Hsu C, Chang SY, Chien SF, Chen YC, Hu FC, Yang JC, Cheng AL, Yeh KH. Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Support Care Cancer. 2014 May; 22(5):1189-97. PMID: 24384684.
      View in: PubMed
    172. Lei Z, Yang J, Zhuang Z. A novel algorithm for determining contact area between a respirator and a headform. J Occup Environ Hyg. 2014; 11(4):227-37. PMID: 24579752.
      View in: PubMed
    173. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014 May; 15(3):173-81. PMID: 24486058.
      View in: PubMed
    174. Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014 Feb; 83(2):174-81. PMID: 24361280.
      View in: PubMed
    175. Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH, Chuadhary I, Goel S. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Invest New Drugs. 2014 Jun; 32(3):445-51. PMID: 24271274.
      View in: PubMed
    176. Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One. 2013; 8(11):e80276. PMID: 24244668.
      View in: PubMed
    177. Tsai TH, Yang CY, Ho CC, Liao WY, Jan IS, Chen KY, Wang JY, Ruan SY, Yu CJ, Yang JC, Yang PC, Shih JY. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 2013 Dec; 82(3):420-5. PMID: 24183104.
      View in: PubMed
    178. Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 01; 31(31):3926-34. PMID: 24101054.
      View in: PubMed
    179. Kwong ML, Neyns B, Yang JC. Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. Clin Cancer Res. 2013 Oct 01; 19(19):5292-9. PMID: 24089442.
      View in: PubMed
    180. Wang X, Yang JN, Li X, Tailor R, Vassilliev O, Brown P, Rhines L, Chang E. Effect of spine hardware on small spinal stereotactic radiosurgery dosimetry. Phys Med Biol. 2013 Oct 07; 58(19):6733-47. PMID: 24018829.
      View in: PubMed
    181. Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood. 2013 Aug 22; 122(8):1399-410. PMID: 23861247.
      View in: PubMed
    182. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol. 2013 Oct; 115(1):61-70. PMID: 23817810.
      View in: PubMed
    183. Kao HF, Lin CC, Yang JC. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol. 2013 Jul; 9(7):991-1003. PMID: 23837762.
      View in: PubMed
    184. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3327-34. PMID: 23816960.
      View in: PubMed
    185. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3342-50. PMID: 23816967.
      View in: PubMed
    186. Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 2013 Jun 15; 190(12):6034-42. PMID: 23690473.
      View in: PubMed
    187. Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013 Jun 10; 31(17):2152-9. PMID: 23650429.
      View in: PubMed
    188. Yang JC. A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncol. 2013 Jun; 14(7):564-5. PMID: 23639469.
      View in: PubMed
    189. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013 May 01; 105(9):595-605. PMID: 23594426.
      View in: PubMed
    190. Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. 2013 Aug; 81(2):280-7. PMID: 23540718.
      View in: PubMed
    191. Long J, Yang J, Lei Z, Liang D. Simulation-based assessment for construction helmets. Comput Methods Biomech Biomed Engin. 2015; 18(1):24-37. PMID: 23495784.
      View in: PubMed
    192. Yang JC, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013 Jun; 13(6):729-36. PMID: 23506556.
      View in: PubMed
    193. Yang JC. The adoptive transfer of cultured T cells for patients with metastatic melanoma. Clin Dermatol. 2013 Mar-Apr; 31(2):209-19. PMID: 23438384.
      View in: PubMed
    194. Liao BC, Lin CC, Yang JC. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013 Mar; 73(4):357-69. PMID: 23479407.
      View in: PubMed
    195. Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013 Feb; 8(2):229-37. PMID: 23328549.
      View in: PubMed
    196. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013 Feb; 36(2):133-51. PMID: 23377668.
      View in: PubMed
    197. Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):418-24. PMID: 23291258.
      View in: PubMed
    198. Cloutier A, Yang J. Design, control, and sensory feedback of externally powered hand prostheses: a literature review. Crit Rev Biomed Eng. 2013; 41(2):161-81. PMID: 24580569.
      View in: PubMed
    199. Lei Z, Yang J, Zhuang Z, Roberge R. Simulation and evaluation of respirator faceseal leaks using computational fluid dynamics and infrared imaging. Ann Occup Hyg. 2013 May; 57(4):493-506. PMID: 23243192.
      View in: PubMed
    200. Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res. 2012 Dec 01; 72(23):6119-29. PMID: 23071066.
      View in: PubMed
    201. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM, Yang JC. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013 Feb; 7(1):112-20. PMID: 23102728.
      View in: PubMed
    202. Silich B, Chrobak P, Siu J, Schlichting A, Patel S, Yang J. Improving safety and efficiency during emergent central venous catheter placement with a needleless securing clamp. Emerg Med J. 2013 Aug; 30(8):683-6. PMID: 22962092.
      View in: PubMed
    203. Liao BC, Yang JC. Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. Transl Lung Cancer Res. 2012 Sep; 1(3):227-9. PMID: 25806186.
      View in: PubMed
    204. Yang JC. Small-cell lung cancer treatment: where is the target? J Thorac Oncol. 2012 Sep; 7(9):1327-8. PMID: 22895135.
      View in: PubMed
    205. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih JY, Lin SB. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013 Jan 01; 328(1):144-51. PMID: 22935675.
      View in: PubMed
    206. Shao YY, Shau WY, Lin ZZ, Chen HM, Kuo R, Yang JC, Lai MS. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer. 2013 Jan; 49(1):106-14. PMID: 22897841.
      View in: PubMed
    207. Lin ZZ, Shau WY, Shao YY, Yang YY, Kuo RN, Yang JC, Lai MS. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study. Oncologist. 2012; 17(10):1294-302. PMID: 22826374.
      View in: PubMed
    208. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):E2127-33. PMID: 22773810.
      View in: PubMed
    209. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol. 2012 Jun; 7(6):973-81. PMID: 22551904.
      View in: PubMed
    210. Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother. 2012 Jun; 35(5):400-8. PMID: 22576345.
      View in: PubMed
    211. Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, Van Waes C, Morgan RA, Dudley ME, Yang JC, Rosenberg SA, Kim HJ. Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg. 2012 Oct; 147(4):744-9. PMID: 22597578.
      View in: PubMed
    212. Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Aug; 77(2):346-52. PMID: 22534669.
      View in: PubMed
    213. Chung KP, Wu SG, Wu JY, Yang JC, Yu CJ, Wei PF, Shih JY, Yang PC. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res. 2012 Jun 15; 18(12):3470-7. PMID: 22510346.
      View in: PubMed
    214. Garg AK, Shiu AS, Yang J, Wang XS, Allen P, Brown BW, Grossman P, Frija EK, McAleer MF, Azeem S, Brown PD, Rhines LD, Chang EL. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer. 2012 Oct 15; 118(20):5069-77. PMID: 22511344.
      View in: PubMed
    215. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May; 13(5):539-48. PMID: 22452895.
      View in: PubMed
    216. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May; 13(5):528-38. PMID: 22452896.
      View in: PubMed
    217. Weksberg DC, Palmer MB, Vu KN, Rebueno NC, Sharp HJ, Luo D, Yang JN, Shiu AS, Rhines LD, McAleer MF, Brown PD, Chang EL. Generalizable class solutions for treatment planning of spinal stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):847-53. PMID: 22445000.
      View in: PubMed
    218. Wei RL, Nguyen ST, Yang JN, Wolff J, Mahajan A. Salvage craniospinal irradiation with an intensity modulated radiotherapy technique for patients with disseminated neuraxis disease. Pract Radiat Oncol. 2012 Oct-Dec; 2(4):e69-e75. PMID: 24674188.
      View in: PubMed
    219. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, Liu P, Allen PK, Azeem SS, Brown PD, Sharp HJ, Weksberg DC, Cleeland CS, Chang EL. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol. 2012 Apr; 13(4):395-402. PMID: 22285199.
      View in: PubMed
    220. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012 Apr 01; 18(7):2039-47. PMID: 22271879.
      View in: PubMed
    221. Kuo YH, Lin ZZ, Yang YY, Shao YY, Shau WY, Kuo RN, Yang JC, Lai MS. Survival of patients with small cell lung carcinoma in Taiwan. Oncology. 2012; 82(1):19-24. PMID: 22269348.
      View in: PubMed
    222. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012 Feb 01; 30(4):433-40. PMID: 22215752.
      View in: PubMed
    223. Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling SK, Bernhardt G, Park JH, Yang JC, Sun PD, Singer A. aß T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities. Immunity. 2012 Jan 27; 36(1):79-91. PMID: 22209676.
      View in: PubMed
    224. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22; 119(12):2709-20. PMID: 22160384.
      View in: PubMed
    225. Li H, Dong L, Zhang L, Yang JN, Gillin MT, Zhu XR. Toward a better understanding of the gamma index: Investigation of parameters with a surface-based distance method. Med Phys. 2011 Dec; 38(12):6730-41. PMID: 22149855.
      View in: PubMed
    226. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, Chu DT, Liao M, Chen YM, Kuo HP, Negoro S, Lam KC, Armour A, Magill P, Fukuoka M. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011 Nov; 6(11):1872-80. PMID: 22011650.
      View in: PubMed
    227. Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res. 2011 Oct 15; 17(20):6459-66. PMID: 22003073.
      View in: PubMed
    228. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011 Oct 07; 11:430. PMID: 21982342.
      View in: PubMed
    229. Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JC. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol. 2011 Oct; 6(10):1663-9. PMID: 21869714.
      View in: PubMed
    230. Yang JC. Melanoma vaccines. Cancer J. 2011 Sep-Oct; 17(5):277-82. PMID: 21952276.
      View in: PubMed
    231. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      View in: PubMed
    232. Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci U S A. 2011 Jul 19; 108(29):E323-31. PMID: 21670269.
      View in: PubMed
    233. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20; 29(21):2866-74. PMID: 21670455.
      View in: PubMed
    234. Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC. Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. J Immunother. 2011 May; 34(4):397-402. PMID: 21499128.
      View in: PubMed
    235. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011 Jul 01; 17(13):4550-7. PMID: 21498393.
      View in: PubMed
    236. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32. PMID: 21439082.
      View in: PubMed
    237. Garg AK, Wang XS, Shiu AS, Allen P, Yang J, McAleer MF, Azeem S, Rhines LD, Chang EL. Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: The University of Texas MD Anderson Cancer Center experience. Cancer. 2011 Aug 01; 117(15):3509-16. PMID: 21319143.
      View in: PubMed
    238. Hanada K, Wang QJ, Inozume T, Yang JC. Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. Blood. 2011 May 05; 117(18):4816-25. PMID: 21300979.
      View in: PubMed
    239. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 01; 29(7):917-24. PMID: 21282551.
      View in: PubMed
    240. Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J Immunol Methods. 2011 Mar 07; 366(1-2):43-51. PMID: 21255579.
      View in: PubMed
    241. Lin CC, Yang JC. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. Drugs. 2011 Jan 01; 71(1):79-88. PMID: 21175241.
      View in: PubMed
    242. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011 Mar; 19(3):620-6. PMID: 21157437.
      View in: PubMed
    243. Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA. Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells. Hum Gene Ther. 2011 Jan; 22(1):107-15. PMID: 20662590.
      View in: PubMed
    244. Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010 Nov-Dec; 33(9):956-64. PMID: 20948441.
      View in: PubMed
    245. Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010 Oct; 33(8):840-7. PMID: 20842052.
      View in: PubMed
    246. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010 Oct; 33(8):828-33. PMID: 20842054.
      View in: PubMed
    247. Yang JN, Ding X, Du W, Pino R. Model-based calculations of off-axis ratio of conic beams for a dedicated 6 MV radiosurgery unit. Med Phys. 2010 Oct; 37(10):5442-7. PMID: 21089780.
      View in: PubMed
    248. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res. 2010 Oct 01; 16(19):4892-8. PMID: 20719934.
      View in: PubMed
    249. Afonso N, Amponsah D, Yang J, Mendez J, Bridge P, Hays G, Baliga S, Crist K, Brennan S, Jackson M, Dulchavsky S. Adding new tools to the black bag--introduction of ultrasound into the physical diagnosis course. J Gen Intern Med. 2010 Nov; 25(11):1248-52. PMID: 20697974.
      View in: PubMed
    250. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010 Dec 15; 16(24):6122-31. PMID: 20668005.
      View in: PubMed
    251. Du W, Yang JN, Chang EL, Luo D, McAleer MF, Shiu A, Martel MK. A quality assurance procedure to evaluate cone-beam CT image center congruence with the radiation isocenter of a linear accelerator. J Appl Clin Med Phys. 2010 Jul 02; 11(4):3297. PMID: 21081890.
      View in: PubMed
    252. Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM. Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. J Immunother. 2010 Jul-Aug; 33(6):626-9. PMID: 20551834.
      View in: PubMed
    253. Du W, Yang J, Luo D, Martel M. A simple method to quantify the coincidence between portal image graticules and radiation field centers or radiation isocenter. Med Phys. 2010 May; 37(5):2256-63. PMID: 20527559.
      View in: PubMed
    254. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010 Apr; 18(4):843-51. PMID: 20179677.
      View in: PubMed
    255. Harding P, Yang XP, Yang J, Shesely E, He Q, LaPointe MC. Gene expression profiling of dilated cardiomyopathy in older male EP4 knockout mice. Am J Physiol Heart Circ Physiol. 2010 Feb; 298(2):H623-32. PMID: 20008274.
      View in: PubMed
    256. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I. Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol. 2010 Jan; 17(1):163-70. PMID: 19777192.
      View in: PubMed
    257. Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, Yang J, Bates SE. Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. Cancer J. 2009 Sep-Oct; 15(5):441-7. PMID: 19826366.
      View in: PubMed
    258. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009 Jul 16; 114(3):535-46. PMID: 19451549.
      View in: PubMed
    259. Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009 May; 116(5):981-989.e1. PMID: 19410956.
      View in: PubMed
    260. Inozume T, Hanada K, Wang QJ, Yang JC. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother. 2009 Feb-Mar; 32(2):109-17. PMID: 19238009.
      View in: PubMed
    261. Du W, Yang J. A robust Hough transform algorithm for determining the radiation centers of circular and rectangular fields with subpixel accuracy. Phys Med Biol. 2009 Feb 07; 54(3):555-67. PMID: 19124954.
      View in: PubMed
    262. Yang JN, Pino R. Analytical calculation of central-axis dosimetric data for a dedicated 6-MV radiosurgery linear accelerator. Med Phys. 2008 Oct; 35(10):4333-41. PMID: 18975679.
      View in: PubMed
    263. Stein WD, Yang J, Bates SE, Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist. 2008 Oct; 13(10):1055-62. PMID: 18827177.
      View in: PubMed
    264. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008 Nov 10; 26(32):5233-9. PMID: 18809613.
      View in: PubMed
    265. Wang QJ, Hanada K, Yang JC. Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas. J Immunol. 2008 Sep 15; 181(6):3769-76. PMID: 18768829.
      View in: PubMed
    266. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008 Sep 01; 14(17):5610-8. PMID: 18765555.
      View in: PubMed
    267. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008 Jul 15; 113(2):293-301. PMID: 18457330.
      View in: PubMed
    268. Yang JC. Vitespen: a vaccine for renal cancer? Lancet. 2008 Jul 12; 372(9633):92-3. PMID: 18602687.
      View in: PubMed
    269. Yan H, Zhu G, Yang J, Lu M, Ajlouni M, Kim JH, Yin FF. The investigation on the location effect of external markers in respiratory-gated radiotherapy. J Appl Clin Med Phys. 2008 Apr 16; 9(2):2758. PMID: 18714280.
      View in: PubMed
    270. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008 Apr; 8(4):299-308. PMID: 18354418.
      View in: PubMed
    271. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6681-8. PMID: 17982122.
      View in: PubMed
    272. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007 Nov-Dec; 30(8):825-30. PMID: 18049334.
      View in: PubMed
    273. Ciangaru G, Yang JN, Oliver PJ, Bues M, Zhu M, Nakagawa F, Chiba H, Nakamura S, Yoshino H, Umezawa M, Smith AR. Verification procedure for isocentric alignment of proton beams. J Appl Clin Med Phys. 2007 Oct 24; 8(4):2671. PMID: 18449154.
      View in: PubMed
    274. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol. 2006 Dec 10; 24(35):5576-83. PMID: 17158543.
      View in: PubMed
    275. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6106-15. PMID: 17062687.
      View in: PubMed
    276. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 06; 314(5796):126-9. PMID: 16946036.
      View in: PubMed
    277. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006 Jul-Aug; 29(4):455-63. PMID: 16799341.
      View in: PubMed
    278. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006 May 20; 24(15):2283-9. PMID: 16710025.
      View in: PubMed
    279. Yang JC, Abad J, Sherry R. Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol. 2006 Apr; 16(2):131-5. PMID: 16564448.
      View in: PubMed
    280. Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother. 2006 Mar-Apr; 29(2):224-31. PMID: 16531823.
      View in: PubMed
    281. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005 Nov-Dec; 28(6):593-8. PMID: 16224277.
      View in: PubMed
    282. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005 Nov 01; 175(9):6169-76. PMID: 16237114.
      View in: PubMed
    283. Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J Immunother. 2005 Nov-Dec; 28(6):551-9. PMID: 16224272.
      View in: PubMed
    284. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005 Dec; 12(12):1005-16. PMID: 16283570.
      View in: PubMed
    285. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005 Sep 01; 23(25):6043-53. PMID: 16087944.
      View in: PubMed
    286. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 01; 23(10):2346-57. PMID: 15800326.
      View in: PubMed
    287. Hanada K, Yang JC. Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing. J Mol Med (Berl). 2005 Jun; 83(6):420-8. PMID: 15759099.
      View in: PubMed
    288. Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol. 2004 Dec 15; 173(12):7209-16. PMID: 15585842.
      View in: PubMed
    289. Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 2004 Nov-Dec; 27(6):472-7. PMID: 15534491.
      View in: PubMed
    290. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004 Nov-Dec; 27(6):478-9. PMID: 15534492.
      View in: PubMed
    291. Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S. PMID: 15448017.
      View in: PubMed
    292. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6367S-70S. PMID: 15448032.
      View in: PubMed
    293. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004 Sep; 10(9):909-15. PMID: 15340416.
      View in: PubMed
    294. Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother. 2004 Jul-Aug; 27(4):259-64. PMID: 15235386.
      View in: PubMed
    295. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature. 2004 Jan 15; 427(6971):252-6. PMID: 14724640.
      View in: PubMed
    296. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003 Sep-Oct; 26(5):385-93. PMID: 12973027.
      View in: PubMed
    297. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003 Aug 15; 21(16):3127-32. PMID: 12915604.
      View in: PubMed
    298. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2003 Aug 01; 9(8):2973-80. PMID: 12912944.
      View in: PubMed
    299. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 Jul 31; 349(5):427-34. PMID: 12890841.
      View in: PubMed
    300. Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother. 2003 Jul-Aug; 26(4):349-56. PMID: 12843797.
      View in: PubMed
    301. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8372-7. PMID: 12826605.
      View in: PubMed
    302. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther. 2003 May 20; 14(8):709-14. PMID: 12804135.
      View in: PubMed
    303. Barrett JC, Bennett LM, Fleming LK, Linehan WM, Liotta LA, Rosenberg SA, Petricoin EF, Staudt LM, Thompson TE, Yang JC. Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. Clin Adv Hematol Oncol. 2003 May; 1(5):302-6. PMID: 16224427.
      View in: PubMed
    304. O'Reilly F, Feldman E, Yang J, Hwu P, Turner ML. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2. J Am Acad Dermatol. 2003 Apr; 48(4):602-4. PMID: 12664026.
      View in: PubMed
    305. Freedman NM, Sundaram SK, Kurdziel K, Carrasquillo JA, Whatley M, Carson JM, Sellers D, Libutti SK, Yang JC, Bacharach SL. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging. 2003 Jan; 30(1):46-53. PMID: 12483409.
      View in: PubMed
    306. Feldman AL, Alexander HR, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer. 2002 Oct 15; 95(8):1637-43. PMID: 12365010.
      View in: PubMed
    307. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002 Oct 25; 298(5594):850-4. PMID: 12242449.
      View in: PubMed
    308. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang RF. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest. 2002 Jun; 109(11):1463-70. PMID: 12045260.
      View in: PubMed
    309. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002 May-Jun; 25(3):243-51. PMID: 12000866.
      View in: PubMed
    310. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):142-52. PMID: 11773163.
      View in: PubMed
    311. Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother. 2002 Jan-Feb; 25(1):82-7. PMID: 11924913.
      View in: PubMed
    312. Yang JN, Mackie TR, Reckwerdt P, Deasy JO, Thomadsen BR. An investigation of tomotherapy beam delivery. Med Phys. 1997 Mar; 24(3):425-36. PMID: 9089594.
      View in: PubMed
    313. Mackie TR, Holmes T, Swerdloff S, Reckwerdt P, Deasy JO, Yang J, Paliwal B, Kinsella T. Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys. 1993 Nov-Dec; 20(6):1709-19. PMID: 8309444.
      View in: PubMed
    314. Yang JN, Murphy AD, Madsen EL, Zagzebski JA, Gilchrist KW, Frank GR, Macdonald MC, Millard CA, Faraggi A, Jaramillo CA, et al. A method for in vitro mapping of ultrasonic speed and density in breast tissue. Ultrason Imaging. 1991 Jan; 13(1):91-109. PMID: 1998250.
      View in: PubMed
    315. Verification procedure for isocentric alignment of proton beams. Journal of Applied Clinical Medical Physics. 8:65-75.
    316. Tomotherapy. International Journal of Imaging Systems and Technology. 6:43-55.
    317. Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. Journal of Applied Clinical Medical Physics. 17:180-189.
    318. Salvage craniospinal irradiation with an intensity modulated radiotherapy technique for patients with disseminated neuraxis disease. Practical Radiation Oncology. 2.
    319. Investigation of 3D dosimetry for an anthropomorphic spine phantom. Journal of Physics: Conference Series. 444.
    320. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma. Journal of Neurosurgery: Spine. 24:829-836.
    321. A quality assurance procedure to evaluate cone-beam CT image center congruence with the radiation isocenter of a linear accelerator. Journal of Applied Clinical Medical Physics. 11:15-26.
    322. Gamma Knife Stereotactic Radiosurgery for Brain Metastases Using Only 3 Pins. Neurosurgery.
    YANG's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description